We are a private biopharmaceutical company developing therapies for ocular disorders


Quethera’s ophthalmic gene therapies use a recombinant adeno-associated viral vector system (rAAV) to introduce therapeutic genes into target retinal cells. Targeted cells effectively become factories producing beneficial proteins to combat disease. The treatment is designed to be administered as a single injection on one occasion into the affected eye. Within a few weeks, the product will provide long lasting therapeutic benefits. The rAAV vector system we are using has been shown to be safe and does not produce a large inflammatory response after injection, making it an ideal platform for the Quethera gene therapies.

Quethera has utilised many of the approaches currently used in traditional drug discovery to produce synthetic small molecule therapeutics by medicinal chemistry or through construction of recombinant monoclonal antibodies. Following identification of suitable druggable targets, the transgenes are deconstructed and reassembled with the addition of novel components which are designed to improve the potency, selectivity, safety and long-term efficacy of our therapeutic proteins which are generated by the products locally within the eye.